Global access Esperion has a broad U.S. commercial infrastructure with approvals in over 40 countries, signaling opportunities for partnerships in market access, co-promotion, acquisition, or revenue-sharing with global innovators seeking U.S. market entry.

Diversified pipeline Beyond bempedoic acid therapies, Esperion is advancing ACLY biology into a diversified pipeline including candidates for Primary Sclerosing Cholangitis and renal diseases, presenting co-development or in-licensing opportunities for cardiometabolic and rare disease assets.

Strategic IP moat Settlement and patent protections around NEXLETOL and NEXLIZET extend market exclusivity to 2040, creating a stable window for potential strategic collaborations, milestone-driven deals, or in-licensing discussions with competitors or new entrants.

Clinical leadership Esperion is actively publishing and presenting data from CLEAR Outcomes and pediatric studies, underscoring a strong clinical development framework that can attract partners for co-development, cross-license, or validation studies in adjacent populations.

Financial runway With substantial funding and a recent merger activity indicating strategic consolidation, there is potential for financing-led partnerships, asset acquisitions, or revenue-sharing deals aligned with Esperion’s growth trajectory andArchimed-backed expansion.